There is no established dose for the CJC-1295 and Ipamorelin stack, because neither peptide is FDA-approved and each has only limited human data. Every figure below is community practice rather than a guideline. The two are dosed separately, then often drawn into a single subcutaneous injection.[1][2][3]
Reviewed for accuracy · Last reviewed July 7, 2026The two peptides are dosed separately, then often drawn into a single injection. Community protocols commonly cite:
Protocols commonly cite roughly 100 mcg of CJC-1295 alongside 200 – 300 mcg of Ipamorelin per dose, typically before bed or after a workout. CJC-1295's human data comes mainly from early-phase pharmacokinetic work, and Ipamorelin's dosing was studied in humans mostly in a postoperative-ileus trial that used weight-based intravenous dosing and did not meet its primary endpoint, so neither maps cleanly onto these subcutaneous community figures.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.